Chimerix Inc.
Funding rounds
2 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2019 | $35 M | Issued in a merger or acquisition | $10 to $50 million | equity | SEC | |
| Feb 2011 | $45 M | No. 2 | $10 to $50 million | equity, options | SEC | |
| Jul 2009 | $16 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Chimerix Inc. had revenue between $5 million and $25 million when it filed its newest notice of a funding round (Jul 2019).
SEC Form D (revenue range) · Jul 2019
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jul 2019
Products and services#
No products or services on record: the address on record now leads to another company's site.
Investors#
24 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Alta Biopharma Partners III Gmbh & Co Beteiligungs KG | Fund or asset manager | not stated | not stated | Held Series D, E and F preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Alta Biopharma Partners III LP | Fund or asset manager | not stated | not stated | Held Series D, E and F preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Alta Embarcadero Biopharma Partners III LLC | Fund or asset manager | not stated | not stated | Held Series D, E and F preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| A.M. Pappas Life Science Ventures III, L.P. | Venture capital | not stated | not stated | Held Series F preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| A.M. Pappas Life Science Ventures IV LP | Venture capital | not stated | not stated | Held Series F preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Canaan Partners VII LLC | Fund or asset manager | not stated | not stated | Held Series D, E and F preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Canaan VII L.P. | Fund or asset manager | not stated | not stated | Held Series D, E and F preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| New Leaf Venture Associates II, L.P. | Venture capital | not stated | not stated | Held Series F preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| New Leaf Venture Management II, L.L.C. | Venture capital | not stated | not stated | Held Series F preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| New Leaf Ventures II, L.P. | Venture capital | not stated | not stated | Held Series F preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| PV III CEO Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series F preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| PV IV CEO Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series F preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Sanderling V Beteiligungs Gmbh & Co KG | Company | not stated | not stated | Held Series A, B, B-1, C, D, E and F preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Sanderling V Biomedical Co Investment Fund LP | Fund or asset manager | not stated | not stated | Held Series A, B, B-1, C, D, E and F preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Sanderling V Biomedical LP | Fund or asset manager | not stated | not stated | Held Series A, B, B-1, C, D, E and F preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Sanderling Venture Partners V Co Investment Fund, LP | Venture capital | not stated | not stated | Held Series A, B, B-1, C, D, E and F preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Sanderling Venture Partners VI Co Investment Fund LP | Venture capital | not stated | not stated | Held Series A, B, B-1, C, D, E and F preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Sanderling Venture Partners V, LP | Venture capital | not stated | not stated | Held Series A, B, B-1, C, D, E and F preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Sanderling Ventures Management V | Venture capital | not stated | not stated | Held Series A, B, B-1, C, D, E and F preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Sanderling Ventures Management VI | Venture capital | not stated | not stated | Held Series A, B, B-1, C, D, E and F preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Sanderling VI Beteiligungs GmbH & Co KG | Company | not stated | not stated | Held Series A, B, B-1, C, D, E and F preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Sanderling VI Limited Partnership | Fund or asset manager | not stated | not stated | Held Series A, B, B-1, C, D, E and F preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Sanderling V LTD Partnership | Fund or asset manager | not stated | not stated | Held Series A, B, B-1, C, D, E and F preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Sanderling V Strategic Exit Fund LP | Fund or asset manager | not stated | not stated | Held Series A, B, B-1, C, D, E and F preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 21 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Heather W. Knight-Trent | Vice President of Regulatory Affairs | Jul 2019 |
| Michael A. Alrutz | Senior Vice President, General Counsel and Corporate Secretary | Jul 2019 |
| Mike Andriole | Chief Business and Financial Officer | Jul 2019 |
| Mike Sherman | Chief Executive Officer and President | Jul 2019 |
| Odin W. Naderer | Vice President, Clinical Pharmacology and Translational Medicine | Jul 2019 |
| Randall A. Lanier | Chief Science Officer | Jul 2019 |
| Roy W. Ware | Chief Manufacturing and Technology Officer | Jul 2019 |
| W. Garrett Nichols | Chief Medical Officer | Jul 2019 |
| George I. Painter, Ph.D | Executive officer | Feb 2011 |
| Gwendolyn P. Painter, M.D., MPH | Executive officer | Feb 2011 |
| Kenneth I. Moch | Executive officer | Feb 2011 |
| George Painter, Ph.D. | Executive officer | Aug 2009 |
| Merrick Almond, Ph.D. | Executive officer | Aug 2009 |
| Rosemary O'Mahony, Ph.D. | Executive officer | Aug 2009 |
| Catherine L. Gilliss | Director | Jul 2019 |
| Edward F. Greissing, Jr. | Director | Jul 2019 |
| Fred A. Middleton | Director | Jul 2019 |
| James M. Daly | Director | Jul 2019 |
| Martha J. Demski | Director | Jul 2019 |
| Mike Sherman | Chief Executive Officer and President | Jul 2019 |
| Patrick F. Machado | Director | Jul 2019 |
| Robert J. Meyer | Director | Jul 2019 |
| Ronald C. Renaud, Jr | Director | Jul 2019 |
| Arthur M. Pappas | Director | Feb 2011 |
| Farah P. Champsi | Director | Feb 2011 |
| George I. Painter, Ph.D | Director | Feb 2011 |
| James M. Niedel | Director | Feb 2011 |
| Kenneth I. Moch | Director | Feb 2011 |
| Seth A. Rudnick, M.D. | Director | Feb 2011 |
| Timothy J. Wollaeger | Director | Feb 2011 |
| Edward E. Penhoet, Ph.D. | Director | Aug 2009 |
| George Painter, Ph.D. | Director | Aug 2009 |
| Graham K. Crooke, M.B.B.S. | Director | Aug 2009 |
About
Company in Durham, United States.